Lab Reference Library / IGFBP-3 (IGF-1 Binding Protein 3)
Advanced & Specialty
IGFBP-3 (IGF-1 Binding Protein 3)
IGFBP-3 · Insulin-Like Growth Factor Binding Protein 3 · IGF BP-3Reference range, optimal functional medicine levels, and why IGFBP-3 is the primary carrier protein for IGF-1 in circulation, how it modifies IGF-1 bioavailability, and why it provides additional context for GH/IGF-1 axis assessment beyond IGF-1 alone, particularly in growth hormone evaluation and cancer risk stratification.
GH Axis MarkerSpecialty Testing
Adult Range2.6 to 8.0 mg/L
Varies ByAge and sex
Paired WithIGF-1, GH
Unitsmg/L
← Back to Lab Reference Library
Category: Advanced & Specialty | Also known as: IGF Binding Protein 3, IGFBP3, Somatomedin Binding Protein
1. What This Test Measures
IGFBP-3 (insulin-like growth factor binding protein 3) is the most abundant IGF-binding protein in human circulation, carrying approximately 75 to 80% of serum IGF-1 in a ternary complex together with IGF-1 and acid-labile subunit (ALS). The ternary complex dramatically extends IGF-1 half-life from minutes to 12 to 16 hours and determines how much IGF-1 is bioavailable to bind tissue receptors at any given moment. Free unbound IGF-1, which constitutes less than 1% of total IGF-1, is the biologically active fraction capable of receptor binding; IGFBP-3 functions as the primary regulatory reservoir controlling this fraction.
IGFBP-3 production is stimulated by growth hormone (GH) through direct hepatic signaling and by IGF-1 itself through a positive feedback loop, making IGFBP-3 a co-marker of overall GH/IGF-1 axis activity. When GH is deficient, both IGF-1 and IGFBP-3 fall in concert, providing more diagnostic certainty than either alone. When GH is excessive (acromegaly), both rise together. IGFBP-3 is also highly sensitive to nutritional status, falling rapidly with protein malnutrition and caloric restriction, making it a useful marker of nutritional reserve independent of its GH axis role.
Beyond GH axis assessment, IGFBP-3 has independent biological actions: it can enter the nucleus and directly regulate gene transcription, it has pro-apoptotic effects in some cell types, and it modulates cell proliferation and differentiation through IGF-independent mechanisms. These intrinsic activities contribute to the emerging interest in IGFBP-3 as both a longevity marker and a potential cancer risk modulator, separate from its role as an IGF-1 carrier.
2. Reference Range and Optimal Levels
| Age Group | Reference Range | FM Optimal Target | Clinical Context |
|---|---|---|---|
| Adults 18 to 25 | 3.4 to 7.8 mg/L | Upper half of range (5.0 to 7.8) | Peak adult binding protein capacity |
| Adults 26 to 35 | 3.1 to 7.5 mg/L | 4.5 to 7.5 mg/L | Slight early decline begins |
| Adults 36 to 50 | 2.6 to 7.0 mg/L | 4.0 to 7.0 mg/L | Mid-life somatopause slope steepens |
| Adults 51 to 65 | 1.8 to 5.9 mg/L | 3.5 to 5.9 mg/L | Significant age-related decline expected |
| Adults above 65 | 1.2 to 4.5 mg/L | Above age-matched median | Low end associated with frailty and sarcopenia |
IGFBP-3 reference ranges are highly age, sex, and assay dependent. Women generally have slightly lower IGFBP-3 than age-matched men. Always use laboratory-specific age-matched normative data for interpretation. IGFBP-3 must be interpreted alongside IGF-1; the pattern of both together provides more diagnostic information than either value in isolation. A single low IGFBP-3 without a concurrent low IGF-1 may reflect nutritional or inflammatory depression rather than GH axis impairment.
3. The IGFBP-3 and IGF-1 Axis: Pattern Interpretation
| IGF-1 | IGFBP-3 | Most Likely Pattern | Clinical Action |
|---|---|---|---|
| Low | Low | GH deficiency, severe malnutrition, or hypothyroidism; both markers depressed by reduced GH stimulus | GH stimulation testing; nutritional assessment; thyroid panel; pituitary MRI if GH deficiency suspected |
| High | High | GH excess (acromegaly); both markers driven upward by excess GH signaling | Oral glucose tolerance test for GH suppression; pituitary MRI; endocrinology referral |
| Low | Normal or high | IGF-1 sequestered in high-IGFBP-3 complex; reduced IGF-1 bioavailability despite adequate production; may occur in insulin resistance or inflammatory states that alter IGFBP-3 proteolysis | Evaluate insulin resistance; check hs-CRP and inflammatory markers; assess free IGF-1 if available |
| Normal | Low | IGFBP-3 depression from malnutrition, severe illness, or hepatic dysfunction without GH axis impairment; IGF-1 maintained by adequate GH but binding protein production is limited | Nutritional assessment; albumin and prealbumin; liver function panel; evaluate for protein insufficiency |
| Normal or high | Low | Increased free IGF-1 bioavailability due to reduced binding capacity; potentially higher IGF-1 receptor stimulation than total IGF-1 alone would suggest | Evaluate cancer risk context; assess total metabolic picture including insulin and glucose |
4. Somatopause: The Age-Related GH/IGF-1/IGFBP-3 Decline
Somatopause is the progressive, age-related decline in GH secretion, IGF-1, and IGFBP-3 that begins in the third decade and accelerates after age 50. By age 60, most adults have GH secretory capacity reduced by 50 to 75% compared to young adulthood, with proportional reductions in IGF-1 and IGFBP-3. This decline is not merely a laboratory finding: it correlates with clinically significant changes including reduced lean muscle mass (sarcopenia), increased visceral adiposity, reduced bone mineral density, impaired recovery from exercise and injury, reduced cardiovascular fitness, and declining cognitive speed. Whether somatopause is a cause of aging-related functional decline or a consequence of other age-related physiological changes remains debated, but the clinical correlations are consistent enough to justify monitoring these markers as part of a longevity panel and implementing the lifestyle and nutritional interventions that slow the decline.
In functional medicine, maintaining IGFBP-3 above the age-matched median is a reasonable longevity target, best pursued through the interventions that support the GH/IGF-1 axis directly: high-quality protein intake, resistance training, optimized sleep (GH is secreted in pulsatile bursts during slow-wave sleep), and correction of nutritional deficiencies that impair GH signaling, particularly vitamin D and zinc. These same interventions that raise IGF-1 will concurrently raise IGFBP-3, since both are GH-driven.
5. Clinical Applications of IGFBP-3 Testing
GH Axis Evaluation
- Adult GH deficiency: GH deficiency reduces both IGF-1 and IGFBP-3 in concert; adding IGFBP-3 to the evaluation increases diagnostic certainty compared to IGF-1 alone; combined low IGF-1 and low IGFBP-3 with a suggestive clinical picture (prior pituitary surgery, cranial radiation, TBI, empty sella) significantly strengthens the case for GH stimulation testing
- Acromegaly monitoring: both IGF-1 and IGFBP-3 are elevated in active acromegaly; IGFBP-3 is used as a secondary confirmatory marker and in monitoring treatment response to somatostatin analogs or surgery, where normalization of both markers indicates successful GH suppression
- Pediatric growth failure: IGFBP-3 is particularly useful in children where IGF-1 levels are highly age-dependent; both markers are depressed in GH deficiency and can distinguish GH deficiency from other causes of short stature
- GH replacement monitoring: in adults on GH replacement therapy for confirmed deficiency, IGFBP-3 and IGF-1 are both monitored to confirm adequate dosing and avoid supraphysiological replacement
Longevity and Metabolic Contexts
- Sarcopenia and frailty risk: declining IGFBP-3 alongside IGF-1 in older adults correlates with progressive muscle loss, reduced strength, and frailty; patients with IGFBP-3 consistently below the age-matched median are candidates for targeted anabolic support strategies including protein optimization, resistance training, and sleep architecture improvement
- Nutritional protein status: IGFBP-3 falls within days of significant protein restriction, more sensitively than albumin (which has a 20-day half-life); IGFBP-3 alongside prealbumin is a practical marker of short-term protein nutritional adequacy in clinical contexts
- Cancer risk context: elevated IGF-1 has been prospectively associated with increased breast, prostate, and colorectal cancer risk in large cohort studies; IGFBP-3 may modify this relationship by determining how much of the elevated IGF-1 is bioavailable to drive cell proliferation; higher IGFBP-3 relative to IGF-1 may buffer some of the proliferative signal, though the clinical translation of this ratio into actionable thresholds requires further evidence
- Insulin resistance: hyperinsulinemia stimulates IGF-1 receptor signaling and reduces IGFBP-3 through increased IGFBP-3 protease activity; patients with significant insulin resistance may have reduced IGFBP-3 relative to their IGF-1 level, increasing free IGF-1 bioavailability
6. How to Optimize IGFBP-3
Exercise and Sleep
- Resistance training: the most potent non-pharmaceutical stimulus for GH secretion and downstream IGF-1 and IGFBP-3 elevation; compound movements (squat, deadlift, press) at moderate to high intensity produce the largest GH pulse; 3 to 4 sessions weekly targeting major muscle groups
- High-intensity interval training (HIIT): acute GH secretion is proportional to exercise intensity; HIIT produces larger GH pulses than steady-state aerobic exercise, driving proportional increases in IGF-1 and IGFBP-3; 2 to 3 HIIT sessions weekly complement resistance training
- Sleep optimization: 70 to 80% of daily GH secretion occurs during slow-wave sleep (stages 3 and 4) in the first two sleep cycles; consistent 7 to 9 hour sleep with early bedtime (10 to 11 PM) maximizes GH secretory amplitude; sleep deprivation significantly blunts GH pulsatility and chronically depresses IGFBP-3
- Minimize late-night eating: GH secretion is inhibited by elevated insulin; eating large meals within 2 to 3 hours of sleep suppresses the overnight GH pulse; time-restricted eating that ends 3 hours before sleep supports maximum GH secretion during the first overnight sleep cycle
Nutrition and Protein
- Adequate protein intake: IGFBP-3 is directly sensitive to protein sufficiency; target 1.2 to 1.6g per kg body weight daily from high-quality complete protein sources; protein restriction depresses IGFBP-3 within days regardless of caloric sufficiency
- Leucine-rich protein sources: leucine is the primary amino acid that stimulates mTOR and GH receptor signaling; whey protein, eggs, beef, and dairy are leucine-dense; 2.5 to 3g of leucine per meal triggers maximal anabolic signaling
- Avoid chronic severe caloric restriction: significant caloric deficit (more than 25% below maintenance) rapidly depresses IGFBP-3 and IGF-1 through GH resistance mechanisms, even when protein intake is adequate; moderate deficit with adequate protein preserves IGFBP-3 better than severe restriction
- Vitamin D optimization (60 to 80 ng/mL): vitamin D receptor signaling is required for normal GH receptor expression in the liver; vitamin D deficiency impairs hepatic IGF-1 and IGFBP-3 production in response to GH; supplementation to optimal range restores IGFBP-3 production in deficient patients
- Zinc adequacy: zinc is required for GH receptor binding and downstream signaling; even mild zinc deficiency impairs GH-stimulated IGFBP-3 production; target serum zinc of 80 to 110 mcg/dL; supplementation at 15 to 30mg daily in deficient patients
Hormonal and Metabolic Context
- Optimize thyroid function: hypothyroidism significantly depresses GH secretion and IGFBP-3 production; free T3 below 3.0 pg/mL impairs hepatic responsiveness to GH; normalizing thyroid function often raises IGF-1 and IGFBP-3 meaningfully without any direct GH intervention
- Correct insulin resistance: hyperinsulinemia increases IGFBP-3 protease activity, accelerating IGFBP-3 degradation and reducing the IGFBP-3 to IGF-1 ratio; insulin sensitization through dietary carbohydrate reduction, metformin, or berberine reduces IGFBP-3 proteolysis and may improve the binding protein balance
- Testosterone optimization in men: testosterone directly stimulates GH secretion and synergizes with IGF-1 and IGFBP-3 in anabolic pathways; men with hypogonadism have significantly lower IGF-1 and IGFBP-3 than eugonadal peers; testosterone restoration raises IGFBP-3 alongside IGF-1
- GH secretagogues (when appropriate): peptides such as tesamorelin, sermorelin, and CJC-1295 with ipamorelin stimulate endogenous GH release through GHRH and ghrelin receptor pathways; they raise both IGF-1 and IGFBP-3 and may be considered in patients with confirmed GH axis decline in the context of clinical symptoms; these are specialist-managed interventions requiring baseline and monitoring labs
7. Related Lab Tests
IGF-1Always Interpret IGFBP-3 Alongside IGF-1
→
GDF-15Longevity Panel Companion; Mitochondrial and Metabolic Stress
→
Telomere LengthBiological Aging Rate Companion Marker
→
Total TestosteroneTestosterone Synergizes with GH/IGF Axis
→
Free T3Hypothyroidism Depresses GH Secretion and IGFBP-3
→
Fasting InsulinHyperinsulinemia Increases IGFBP-3 Protease Activity
→
8. Clinical Perspective
Clinical Perspective
I use IGFBP-3 in two distinct clinical contexts and they require different interpretive frameworks. In the GH deficiency evaluation, IGFBP-3 is a confirmation marker: when a patient has IGF-1 at the bottom of the reference range and IGFBP-3 also at the lower quartile for their age alongside a clinical history of pituitary dysfunction, traumatic brain injury, or prior cranial radiation, that combined pattern gives me enough confidence to pursue GH stimulation testing without over-relying on a single IGF-1 value. In the longevity panel context, I am using IGFBP-3 alongside IGF-1 to characterize whether the GH axis is tracking ahead of, at, or behind where it should be for a patient's chronological age. A 55-year-old man with IGFBP-3 of 4.8 mg/L, which is well above the midpoint of his age-matched range, alongside a consistent resistance training program, 8 hours of quality sleep, and adequate protein intake, is demonstrating a well-preserved GH axis. A 42-year-old woman with IGFBP-3 of 1.9 mg/L and IGF-1 at the bottom of her range is showing me a GH axis that is aging faster than her chronological age suggests it should, and that finding motivates an investigation into her sleep architecture, protein intake, thyroid status, and insulin sensitivity. The number turns a symptom cluster into a measurable, addressable biological pattern.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
9. Frequently Asked Questions
What does IGFBP-3 measure and why does it matter?
IGFBP-3 is the primary carrier protein for IGF-1 in circulation, carrying 75 to 80% of serum IGF-1 in a ternary complex that extends IGF-1 half-life and regulates how much IGF-1 is bioavailable to bind tissue receptors. IGFBP-3 levels reflect GH/IGF-1 axis activity, nutritional protein status, and thyroid function. Low IGFBP-3 alongside low IGF-1 suggests GH deficiency or malnutrition; the pattern of both markers together is the key diagnostic signal.
Why is IGFBP-3 always ordered alongside IGF-1?
IGF-1 and IGFBP-3 are co-regulated by GH: both fall with GH deficiency and rise with GH excess. The combination provides more diagnostic certainty than either alone. Additionally, the ratio of IGFBP-3 to IGF-1 reflects the binding protein environment determining IGF-1 bioavailability: low IGFBP-3 relative to IGF-1 means more free IGF-1 is available to drive tissue receptor binding, with implications for both anabolic signaling and cancer risk context.
What causes low IGFBP-3?
The most common causes of low IGFBP-3 in functional medicine practice are GH deficiency (pituitary dysfunction, prior cranial radiation, TBI, or functional GH axis decline from somatopause), protein malnutrition or caloric restriction (IGFBP-3 falls within days of inadequate protein intake), hypothyroidism (which impairs hepatic GH responsiveness), hyperinsulinemia and insulin resistance (which increase IGFBP-3 proteolytic degradation), chronic inflammatory states, and hepatic insufficiency (since IGFBP-3 is produced primarily in the liver).
How do lifestyle changes affect IGFBP-3?
IGFBP-3 responds to the same interventions that support the GH/IGF-1 axis: resistance training (the strongest non-pharmaceutical GH stimulus), high-intensity exercise, optimized slow-wave sleep (where 70 to 80% of GH is secreted), adequate protein intake of 1.2 to 1.6g per kg daily, vitamin D optimization to 60 to 80 ng/mL, and zinc adequacy. Avoiding large meals in the 2 to 3 hours before sleep preserves the overnight GH pulse that drives IGFBP-3 production. These changes typically produce measurable IGFBP-3 improvement within 8 to 12 weeks when the deficit is lifestyle-driven rather than structural.
Does high IGFBP-3 indicate cancer risk?
The cancer risk relationship with IGFBP-3 is complex and somewhat the inverse of the IGF-1 cancer risk concern. Higher IGF-1 has been prospectively associated with increased breast, prostate, and colorectal cancer risk; higher IGFBP-3 may partially buffer this risk by sequestering IGF-1 and reducing its bioavailability for receptor binding. However, IGFBP-3 also has direct pro-apoptotic effects in some cell types through IGF-independent mechanisms. Very high IGFBP-3 (above the reference range) without a clear GH excess explanation warrants evaluation; within-range variation should be interpreted in the full clinical context rather than in isolation.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
IGFBP-3 completes the IGF-1 picture by revealing the binding protein environment that controls how much of the available IGF-1 actually reaches tissue receptors.
IGFBP-3 and IGF-1 together characterize GH axis function, biological aging rate, and anabolic reserve more completely than either alone. Schedule a consultation for a comprehensive growth hormone axis and longevity panel assessment.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.